Establishment of a prognostic model for HER2 low expression breast cancer with lung metastasis
10.13315/j.cnki.cjcep.2025.11.005
- VernacularTitle:HER2低表达乳腺癌肺转移预后模型的建立
- Author:
Zirui TAN
1
;
Jiaxian MIAO
;
Zhenyu MENG
;
Ang LI
;
Yuqing LUO
;
Huirui ZHANG
;
Yan DING
;
Yueping LIU
Author Information
1. 河北医科大学第四医院医务处,石家庄 050011
- Publication Type:Journal Article
- Keywords:
breast cancer;
HER2 low expression;
lung metastasis;
consistency of HER2 status;
prognostic model
- From:
Chinese Journal of Clinical and Experimental Pathology
2025;41(11):1427-1435
- CountryChina
- Language:Chinese
-
Abstract:
Purpose This study aimed to evaluate the consistency of human epidermal growth factor receptor 2(HER2)status between primary breast cancer lesions and lung metastatic lesions and to establish a prognostic model for predicting the survival rate of HER2 low expression(HER2-low)breast cancer patients with lung metastasis.Methods Clinicopathological data from a cohort of 252 patients with breast cancer and lung metastasis were retrospec-tively analyzed.Results 50.00％of the patients had HER2-low expression in metastatic lesions,and HER2-low ex-pression was the most prevalent subgroup in both primary and metastatic lesions.A discordance in HER2 status be-tween primary and metastatic sites was observed in 28.07％of cases.The most frequent shift was from HER2-zero in the primary tumor to HER2-low expression in the metastasis(12.28％of all cases).Estrogen receptor(ER)status,menopausal status,and histological type were identified as independent prognostic factors for overall survival(OS)by univariate and multivariate Cox regression analyses.A prognostic model incorporating these factors was constructed to predict 3-year and 5-year survival.The model demonstrated area under the curve(AUC)values of 0.765 and 0.780 for 3-year and 5-year OS in the training cohort,and 0.667 and 0.706 in the validation cohort,respectively.Conclu-sion HER2-low expression is the most common subtype among breast cancer patients with lung metastasis.The ob-served shift from HER2-zero in primary lesions to HER2-low in metastases underscores the clinical necessity of re-biop-sy at metastatic sites.The developed prognostic model effectively predicts OS in this patient population.
